The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Using MRD-driven therapy in CLL: current and future applications
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, briefly discusses the use of measurable residual disease (MRD) to drive therapy in chronic lymphocytic leukemia (CLL). Dr Munir notes that MRD-driven therapy aims to achieve the deepest remission possible, with the goal of potentially achieving a functional cure in some patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
